Full-Time

Account Executive

East Region

McKesson

McKesson

10,001+ employees

Pharmaceuticals and medical supplies distributor.

Compensation Overview

$139k - $231.6k/yr

+ Bonus + Long-Term Incentive

No H1B Sponsorship

Pennsylvania, USA + 2 more

More locations: Jackson Township, NJ, USA | New York, NY, USA

Hybrid

East Region; ideal candidates live in NJ, NY, or PA. Up to 50% travel; remote/home office not 100% remote.

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
Computer Networking
Salesforce
Data Analysis

Get referred to McKesson

See people who can refer or advise you

Requirements
  • 4+ years of progressive experience in sales or service
  • 4+ years of experience with professional communication with ability to express complex messages, sell services through written/verbal communications to a variety of practice stakeholders (physicians and admin staff)
  • Healthcare experience in Oncology or Rheumatology or multi-specialty
  • Bachelor’s degree in business related field preferred or equivalent work experience with an emphasis in Business, Health Administration, Communications, or other healthcare related field
  • Degree or equivalent and typically requires 4+ years of relevant experience
  • 4+ years of relevant experience in sales or related field
  • Must be authorized to work in the US unrestricted – This position is not eligible for sponsorship
  • Ability to travel up to 50% within the territory
  • Valid driver's license with a clean driving record
Responsibilities
  • Strategizes, prioritizes, and executes sales activities to create opportunities with new and existing practices, while leading Quarterly Business Reviews (QBRs), conducting monthly customer meetings, and facilitating end-of-quarter business discussions to drive growth, strengthen partnerships, and ensure alignment on customer goals and performance
  • Understand the practice’s business challenges, strategies, and priorities and how McKesson Provider Solutions can help address those needs
  • Identifies the most strategically important customers, decision makers/influencers and personally develops relationships with them
  • Actively participates in a continuous customer planning process, in assessing customer value as well as by planning and shaping account strategies
  • Fully engages the practice in planning the account activities
  • Proactively Develops and expands network to generate opportunities
  • Understand practice processes, buying cycles and decision drivers as well as their current and future needs. Articulates ROI/value of products, services, and solutions
  • Meets the needs and concerns of the practices—considers how actions or plans will affect practices; responds quickly to meet needs and resolves problems; avoids over commitments
  • Sets up customer feedback systems—Implements effective ways to monitor and evaluate concerns, issues, and satisfaction within each practice and to anticipate the practices’ needs
  • Educates the practices—Shares information with practices to build their understanding of issues and capabilities; is regarded by the practice as the thought leader in this industry
  • Builds collaborative relationships—Builds rapport and trusted advisor relationships with the practices; demonstrates empathy towards the customer in all situations and uses that empathy to successfully resolve issues; establishes regular meetings to be in front of the customer
  • Increases number of opportunities, average deal value, win rate while reducing sales cycle time
  • Build a sales pipeline of high-quality opportunities and disqualifying unlikely and poorly fit opportunities
  • Prepares accurate and timely sales forecasts
  • Conducts win/loss analysis and sharing insights with other stakeholders
  • Understand the practice’s decision drivers from their perspective (options available, financial benefit/costs) and the implications that buying decisions have on both McKesson and the practice
  • Draws upon knowledge of competitors and payers to communicate valuable insight on those issues that deliver results for both McKesson Provider Solutions and the practice
  • Understand Provider Solutions business units (BU) and their relationships to each other within Provider Solutions and McKesson
  • Prepares and delivers Quarterly Business Reviews; interprets the data to provide valuable insight and help the practice make decisions to increase profitable revenue for both the practice and McKesson Provider Solutions
  • Identifies, collects, and organizes data for analysis and decision-making; articulates trends in the healthcare industry and develops new opportunities
  • Understand McKesson products and value-added services and how they compare/contrast to the competition
  • Knows how the competition positions their products and/or services in the market and to the customer and can leverage the weaknesses to McKesson Provider Solutions' advantage
  • Jointly identify and drive the strategic vision and partnership between the customer and McKesson, ensuring alignment in expectations for the product/service and the desired outcomes. Establishing multiple levels of relationship with the customer (high and wide: at the user level, department head level, and senior management), engaging Sr. Leadership when appropriate
  • Day-to-day account management, relationship building, selling, and troubleshooting. Act as both the internal and external customer liaison, serving as the customer advocate, including monitoring, and supporting all activity and chasing problem resolution through the appropriate part of our organization and escalating customer issues quickly if problems are not being addressed sufficiently. Works with operations, finance, customer care, GPO, generics, sales effectiveness, contracts, and legal among other internal teams
  • Analysis of sales reports and customer trends to proactively identify and capture opportunities
  • Identify opportunities for cross-selling new products across McKesson, selling add-on services and working with the sales team to identify opportunities and drive them to closure
  • Participating and deployment of training and education key learnings
  • Travel and Expense booking and reporting
  • Sales Force: Document activity, customer notes/status updates, maintenance of current and potential customer profiles and utilize to complete/adhere to company processes
Desired Qualifications
  • Intermediate proficiency with MS Office, Salesforce.com or CRM, ideally with SAP experience
  • Experience with delivering customer quarterly business reviews or analyzing performance and communicating value to customers
  • Demonstrated success in customer growth and retention
  • Demonstrated capabilities in establishing executive level relationships and conducting executive-level meetings and presentations
  • Demonstrates leadership qualities and the ability to build and coordinate a team of professionals to accomplish a common goal/objective to deliver customer value
  • Experience with pharmaceutical products (preferably oncology) and buy-and-bill model

McKesson is a global healthcare distributor and services provider. It buys pharmaceuticals and medical products from manufacturers and distributes them to pharmacies, hospitals, and other healthcare facilities, acting as an intermediary in the supply chain. Its core work includes logistics and supply chain management, ensuring medicines and medical supplies reach customers on time and safely. McKesson also offers technology solutions to help healthcare providers manage operations and procurement. Compared with competitors, it leverages a very large-scale network and integrated services—combining distribution, logistics, and technology—across providers, pharmacies, and manufacturers. The company aims to support the healthcare system by keeping essential medical supplies available and helping healthcare facilities run more efficiently, ultimately improving patient care.

Company Size

10,001+

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1833

Get referred to McKesson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Automation and analytics can lift throughput and lower operating friction.
  • The $5 billion buyback authorisation supports per-share earnings growth.
  • Specialty, biosimilar, and OTC exposure diversifies revenue beyond generic distribution.

What critics are saying

  • Opioid litigation still threatens cash flow, dividends, and lender confidence.
  • Amazon Pharmacy and direct-to-consumer channels compress traditional distribution economics.
  • Regulatory scrutiny of drug handling and pricing creates recurring compliance costs.

What makes McKesson unique

  • McKesson serves as the logistical backbone of North American healthcare.
  • Four segments span pharmaceuticals, oncology, prescription technology, and medical-surgical supplies.
  • RxTS platforms like CoverMyMeds deepen pharmacy and biopharma workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
50states Today
Jun 24th, 2026
McKesson selects Moore, Oklahoma for $179 million state-of-the-art pharmaceutical distribution center.

McKesson selects Moore, Oklahoma for $179 million state-of-the-art pharmaceutical distribution center. Oklahoma Governor and Local Officials Tout Cleveland County as National Healthcare Supply Chain Hub Not only is this a project announcement, this is also a market signal. Moore and Cleveland County officials can deliver at scale, move at speed, and support mission-critical operations." - Lawrence McKinney, CCEDC President MOORE, OK, UNITED STATES, June 24, 2026 /EINPresswire.com/ - McKesson Corporation, a Fortune 100 company that serves as a logistical and operational backbone of the U.S. healthcare system, has selected Moore, Oklahoma, as the location for a highly automated distribution facility at the North Moore Industrial Park. The new facility will replace an existing distribution center, expanding capacity and modernizing capabilities to support future demand. The investment underscores McKesson's continued commitment to strengthening the reliability, security, and efficiency of the healthcare supply chain and to further strengthening its strong, digitally connected distribution network across the U.S. The project represents: 1. The first large-scale industrial investment in the North Moore Industrial Park 2. A defining moment for City leadership and Moore's evolution as a major Cleveland County employment center, with over 200 jobs. 3. Another successful milestone in Cleveland County's transition to a unified, countywide economic development strategy The facility will support the efficient distribution of pharmaceuticals and medical products across a multi-state region. It will expand the capacity of McKesson's U.S. distribution network, helping ensure pharmacies, hospitals, and providers have consistent access to the products their patients rely on. McKesson distributes approximately one-third of all pharmaceuticals in North America and operates a digitally connected, automated distribution network designed to support the delivery of complex therapies to every care setting, from Main Street pharmacies to hospitals. Its decision to locate in Moore followed a rigorous evaluation of competing markets across the central United States. "Not only is this a project announcement; this is also a market signal," said Lawrence McKinney, CEO of the Cleveland County Economic Development Coalition. "McKesson had multiple competitive options across several states. They chose this location because Moore and Cleveland County officials can deliver at scale, move at speed, and support mission-critical operations. This win establishes our region as a serious contender for national and global investment." "This investment by McKesson is a powerful endorsement of Oklahoma's pro-business environment and our ability to compete for major projects on a national stage," said Governor Kevin Stitt. "We have worked hard to make Oklahoma a Top Ten state for business, and this project reflects that progress. With our central location, strong workforce, and commitment to supporting industry, Oklahoma is the ideal place for companies like McKesson to grow and succeed." The City of Moore played the leading role in ensuring the site was competitive at the national level. "We made intentional, strategic investments to ensure this site could compete with larger metro markets," said Mark Hamm, Mayor of Moore. "Through infrastructure planning and the creation of a Tax Increment Financing district, we delivered a site that meets the expectations of a Fortune 10 company. McKesson's decision validates the hard work led by Assistant City Manager Deidre Ebrey and City Manager Brooks Mitchell." STRATEGIC INVESTMENT IN NATIONAL HEALTHCARE INFRASTRUCTURE The 330,000-square-foot facility will serve as a regional pharmaceutical distribution hub, combining digitally enabled logistics, state-of-the-art automation, precision inventory management, and expanded cold-chain capacity to help ensure that critical medicines reach customers safely and efficiently. The site will also increase capacity and throughput and strengthen operational resilience with 100% standby power to support safe operations in adverse conditions. "The healthcare supply chain grows more complex, from supporting advanced therapies with specialized handling and storage to navigating modernization, security, and supply constraints. Patients are counting on consistent, reliable access to critical therapies," said Gene Cavacini, President, U.S. Pharmaceutical Distribution, McKesson. "This investment strengthens our ability to deliver with speed, precision, and resilience, while expanding capacity to better serve Oklahoma, Texas, and the surrounding region." Josh Moore, Kadean Construction, Industrial Director, is excited to be the construction partner for this distribution facility with two valued repeat clients, McKesson and Scannell Properties. POWERED BY PARTNERSHIP: A NEW MODEL FOR ECONOMIC DEVELOPMENT At the core of this win is a fully aligned partnership among Cleveland County, the City of Moore, and the CCEDC, operating as a unified economic development engine. "This project demonstrates what is possible when Cleveland County, the City of Moore, and the CCEDC are fully aligned," said District 2 County Commissioner Jacob McHughes. "We are no longer competing as individual jurisdictions; we are competing as one county. That level of coordination changes outcomes, and this project proves it." IMMEDIATE AND LONG-TERM ECONOMIC IMPACT The project delivers both near-term economic stimulus and long-term structural impact according to an economic impact analysis conducted by the Coalition: Capital Investment & Jobs: $179 million total capital investment 200+ direct jobs 633 total jobs (direct + indirect + induced impacts) Construction Phase (2026-2028): 1156 (direct + indirect + induced) jobs $85.7 million in wages $28 million in tax revenue Ongoing Economic Contribution $118 million annual GDP impact "This is the type of project that strengthens the entire regional economy," said District 3 County Commissioner Rusty Grissom. "It expands our tax base, creates quality jobs, and positions Cleveland County within one of the most critical, recession-proof industries in the country." FROM PROJECT TO PLATFORM: BUILDING A LOGISTICS AND HEALTHCARE CLUSTER McKesson's investment does more than provide jobs; it strengthens healthcare infrastructure and expands capacity to serve providers and patients across the region, while establishing Moore and Cleveland County as a credible destination for advanced logistics, healthcare infrastructure, and supply chain-dependent industries. "This is a platform investment," said District 1 County Commissioner Rod Cleveland. "When a company like McKesson selects your community, it reduces perceived risk for every company that follows. This project creates momentum, and we intend to build on it." With access to major interstate corridors, proximity to the Oklahoma City metro workforce, and coordinated regional leadership, Cleveland County continues to enhance its position to attract additional high-value, high-impact employers. EXECUTION AS A COMPETITIVE ADVANTAGE This announcement marks a turning point in how economic development is executed in Cleveland County. "This project proves that alignment, speed, and execution create successful deals," said Matt Clouse, CCEDC Chairman. "We have built a model where Cleveland County, our municipalities, and our partners are learning to operate as one team, and that is now our competitive advantage." Erica Millar Cleveland County Economic Development Coalition +1 405-315-3444 [email protected] Visit 50 States Today on social media: LinkedIn Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. 50 States Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Cadillac News
Apr 7th, 2026
Latent raises $80M to close the gap between diagnosis and treatment.

Latent raises $80M to close the gap between diagnosis and treatment. * Business Wire * 2 hrs ago SAN FRANCISCO-(BUSINESS WIRE)-Apr 7, 2026- Latent, the clinical-AI company accelerating access to life-saving medications, has raised an $80M Series A co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Today, Latent works with 50% of the top 20 U.S. health systems. Sri Somasundaram (left), Rish Jain (right), Co-CEOs and Co-Founders of Latent Modern medicine has advanced faster than the systems that deliver it. Today in the U.S., a patient and their doctor will sit together, look at a diagnosis, and decide on a treatment. In 42% of critical cases, that life-saving medication will be delayed or denied and may not reach the patient. This is not because the medicine doesn't exist or the doctor made the wrong call, but because every therapy a patient receives must pass through a gauntlet of clinical documentation, payer rules, and pharmacy coordination. Discover more Coupon publications Local sports coverage That gauntlet is currently held together by manual labor: clinicians toggling between systems, pharmacy teams re-keying information, staff navigating phone trees to prove what a patient's own chart already shows. The work is clinical in nature; it involves interpreting labs, applying treatment criteria, matching diagnoses to coverage rules. It is among the highest-stakes knowledge work in healthcare, and it is done almost entirely by hand. For the first time, AI makes it possible to close the distance between a therapeutic decision and a patient receiving therapy. Latent is building the Clinical Reasoning Engine. The engine performs clinical knowledge work by reasoning through patient data, interpreting drug criteria, extracting key evidence, and orchestrating workflows across stakeholders. By connecting the EHR, payer guidelines, pharmacy operations, and patient engagement with a single engine, Latent replaces the fragmented, manual work that sits between a doctor's order and a patient's treatment with AI agents that perform it instantly and at scale, all to help providers move a patient from decision to therapy the same day. Latent started with prior authorization, the most acute expression of the problem: high provider burnout, high stakes where patients can abandon therapy, and complex clinical decision-making. Meeting that challenge required mastering drug criteria and reasoning over medical records. Having demonstrated its ability to deliver on one of healthcare's hardest problems, the company is now expanding its engine across every process where clinical knowledge must be translated into action. Today, over2 million patientsannually are accessing life-changing medications faster because of Latent. Over the past year, the company has scaled from 4 to more than 45 health system partners and now serves 50% of the top 20 U.S. health systems - including Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Across nearly every specialty and therapeutic area, Latent is reducing denials by more than 30% and enabling clinicians to serve twice as many patients. Discover more Senior lifestyle products Crosswords and contests Crossword puzzle books Looking to the future, Latent's Clinical Reasoning Engine will be applied proactively to identify when patients should begin therapy and ensure they stay on it. Every day, treatments that could help patients are delayed, denied or not identified. The company is building the infrastructure for the intersection of clinicians, patients, and payers, powering the knowledge work that determines what care patients actually receive. With the Series A financing, the company will expand its health system footprint, deepen the platform connecting hospitals, payers, pharmacies, and patients, continue investing in the reliability and trust required to operate in healthcare, and scale the team. Latent is a home for exceptional talent who believe responsibility doesn't end at diagnosis, it extends to making sure patients actually receive care. About Latent Health Latent Health is the leading AI platform for medication access. The company brings clinical intelligence directly into the patient record, helping care teams move patients from clinical decision to therapy faster and more reliably. Latent is helping more than 2 million patients annually and is trusted by more than 45 of the nation's leading health systems, including Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Founded by Sriram Somasundaram and Rishabh Jain, Latent has raised $80M in total funding from Transformation Capital, Spark Capital, McKesson Ventures, Conviction, General Catalyst, Y Combinator, and others. To learn more, visit latenthealth.com, and see open roles at latenthealth.com/careers. KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE DATA MANAGEMENT HOSPITALS HEALTH TECHNOLOGY TECHNOLOGY PUB: 04/07/2026 04:23 PM/DISC: 04/07/2026 04:23 PM From the Web Powered by

Yahoo Finance
Apr 7th, 2026
BofA cuts McKesson price target to $1,000 on GLP-1 pricing pressure concerns

Bank of America analyst Allen Lutz has lowered McKesson Corporation's price target to $1,000 from $1,040 whilst maintaining a Buy rating. The analyst cited concerns that rapidly declining cash-pay GLP-1 prices are shifting prescriptions away from insurance coverage. BofA warned that strong growth in cash-pay scripts for Wegovy and Zepbound could pressure McKesson's fiscal year 2027 EBIT guidance in its Prescription Technology Solutions segment, potentially falling below market expectations. Separately, McKesson announced in March that CFO Britt Vitalone will retire after 20 years with the company. Kenny Cheung will succeed him as executive vice president and CFO on 29 May 2026. Vitalone will remain as a strategic adviser during the transition.

TipRanks
Apr 7th, 2026
McKesson Secures New $2 Billion Senior Credit Facilities - TipRanks.com

The latest update is out from McKesson ( ($MCK) ). On April 1, 2026, McKesson subsidiaries, including McKesson Medical-Surgical Top Holdings, entered into a new sen...

AInvest
Apr 2nd, 2026
MedMira reports Q2 FY2025 results, signs distribution agreement with McKesson, and publishes clinical trial results.

MedMira reports Q2 FY2025 results, signs distribution agreement with McKesson, and publishes clinical trial results. Wednesday, Apr 1, 2026 10:11 pm ET 1min read MedMira reported Q2 FY2025 financial results with revenue of $24,503, a gross profit of $18,132, and operating expenses of $423,180. The company signed a distribution agreement with McKesson, expanded its product offering, and published clinical trial results for its Multiplo Complete Syphilis test. Clinical trials for the Multiplo TP/HIV self-test have progressed, and the company is working on its MiROQ technology. Ask Aime: How does MedMira's Q2 FY2025 financial performance align with its long-term growth prospects? Aime insights. What powerful indicators do day traders use? How do operating cash flows compare among top e-commerce giants over the decade? How is the S&P 500 performing today, and could you explain the reasons behind it? Among the Magnificent 7, which stock offers the best value to buy now?